Tablets & Capsules

TC0319

Issue link: https://www.e-digitaleditions.com/i/1087673

Contents of this Issue

Navigation

Page 27 of 51

26 March 2019 Tablets & Capsules The scope included what needed to be transferred (process, analytical, packaging, and equipment), any anticipated major changes or need for development, and markets where the products would ship. 2. Product and process overview Product description. We detailed the qualitative and quantitative registered formula for the product, which was a chewable tablet. We provided the claim/tab, international units, any overage, quantity per tablet, and percentage formula for each medicinal and non-medicinal ingredient. Process overview. We listed all process steps and equip- ment from the sending site. We also included a flow dia- gram, which is ideal. Packaging overview. We listed all the packaging SKUs and mentioned any that were discontinued. in the tech transfer report. Most importantly, the tech transfer report should include a section with lessons learned. This section should compile the receiving unit's debrief notes to recognize the team's challenges, achievements, and efforts. Example tech transfer plan Let's look at an example tech transfer project in which a client of mine decided to transfer a well-recognized OTC brand from a long-term CMO to a new CMO. 1. Purpose and scope In this section, we discussed the drivers for the transfer and indicated the receiving CMO. In this case, the main drivers for the change were costs and a risk that the cur- rent CMO might go out of business due to a lack of investment in its aging facility. Table 1 Example initial risk assessment Item Level of change Risk Risk mitigation Active ingredient Major Will use a different supplier of directly compressible active ingredient granulation (>25 percent of the total blend composition), which may affect compression and tablet parameters. Tested lots from three suppliers for chemical and physical properties. Will conduct pilot studies to assess the compression parameters required to achieve the desired quality attributes. Excipients Minor Will use the same suppliers. Sources were already qualified at receiving site. Composition/formulation Minor Potential change to the percentage of lubricant used, within SUPAC limits. Will monitor sticking issues during pilot batches. Expect that a slight increase in lubricant amount will resolve the issue per sending-site development studies. Batch size Minor Receiving site will run a similar batch size to that of the sending site and within equipment working volumes. Will perform blend-time studies on pilot and scale-up batches. Major equipment Moderate Moving from a high-shear blender to a V-blender with a high-speed intensifier bar. Will perform blend-time studies on pilot and scale-up batches to confirm the uniformity of the final blend. In-process controls Minor Will maintain the same or more stringent in-process controls. Will confirm in-process controls during pilot and scale-up studies. Analytical test methods—Raw materials and finished product None No changes planned or will use USP methods. Will verify all compendial methods. Will transfer finished methods. Finished product specifications None No changes planned. Will use the same release specifications. Stability None No changes planned. Will use the same stability specifications. Primary packaging components Moderate Planning to change the bottle supplier. Will use the same type of resin but a different source. Will perform accelerated and long- term stability studies on pilot study batches.

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC0319